Table 3.

Clinical outcomes in PVR+ versus PVR- women.

	PVR+ n = 7	PVR- n = 22	P value
Cardiovasculara
Heart failure requiring intensification of therapy, n (%)	1 (14)	3 (14)	0.97
NYHA deterioration ≥2 grades, n (%)	1 (14)	2 (9)	0.76
Atrial or ventricular arrhythmia, n (%)	0 (0)	0 (0)	1.00
Endocarditis, n (%)	0 (0)	0 (0)	1.00
Thromboembolic event, n (%)	0 (0)	0 (0)	1.00
Maternal death, n (%)	0 (0)	0 (0)	1.00
Obstetric
Premature rupture ofthe membrane, n (%)	0 (0)	2 (9)	0.27
Pregnancy-induced hypertension, n (%)	1 (14)	0 (0)	0.09
Pre-eclampsia, n (%)	0 (0)	0 (0)	1.00
Infection, n (%)	0 (0)	1 (5)	0.44
Bleeding, n (%)	0 (0)	1 (5)	0.42
Premature labor, n (%)	0 (0)	3 (14)	0.15
Gestational age	38.7 ± 1.4	38.4 ± 1.6	0.62
Mode of delivery, n (%)			0.65
Vaginal	5 (71)	13 (62)
Caesarean section	2 (29)	8 (38)
Fetal/neonatal
APGAR score at 1 min	8 (5–9)	8.5 (7–9)	0.17
APGAR score at 5 min	9 (8–9)	9 (9–9)	0.50
Birthweight	2734 ± 430	3079 ± 394	0.10
NICU admission, n (%)	1 (14)	4 (18)	0.40

Data are represented as mean ± SD, median (IQR) or frequency (percent).

NICU, neonatal intensive care unit; NYHA, New York Heart Association Functional class; PVR, pulmonary valve replacement.

^aNon-mutually exclusive events.